Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Only three in 10 Americans have HIV under control: government report

Just 30 percent of Americans living with HIV have the virus in check, putting others at risk of infection, U.S. health officials said yesterday. The report by the U.S. Centers for Disease Control and Prevention (CDC) found that 840,000 of the 1.2 million people infected with HIV in 2011 were not consistently taking anti-HIV drugs that keep the virus suppressed at very low levels.

Published
13 hours ago
From
Reuters
Looking to a New Era for Women's HIV Prevention: Zeda Rosenberg

Zeda Rosenberg, Chief Executive Offiver of the International Partnership for Microbicides, says: "While there is much progress to celebrate in HIV treatment and prevention, protecting women remains a major challenge. AIDS is the number-one killer of women ages 15 to 44 worldwide. Women are biologically more vulnerable to infection and face deep-rooted gender inequities that increase their risk. In sub-Saharan Africa, where the epidemic has taken the greatest toll, young women are at least twice as likely to contract HIV as young men."

Published
13 hours ago
From
Huffington Post
European Commission approves Rezolsta ® , a new once - daily , fixed - dose HIV therapy combining darunavir and cobicistat

Janssen-Cilag International NV (Janssen) today announced that the European Commission (EC) has approved the use of REZOLSTA ® (darunavir/cobicistat) in combination with other antiretroviral (ARV) medicinal products for the treatment of human immunodeficiency virus - 1 (HIV - 1) infection in adults aged 18 years or older. "REZOLSTA ® eliminates the need to take a boosting agent in a separate tablet with once - daily darunavir, reducing the pill burden for patients," said Christiane Moecklinghoff, M.D Ph.D, Medical Director, Virology, Janssen EMEA.

Published
25 November 2014
From
Janssen
START Study Could Change How We Look at HIV Treatment, and HIV Itself

Have you heard of the START (Strategic Timing of Antiretroviral Treatment) study? In my opinion, it is probably the most important study currently running. It generates strong views, both for and against initiating antiretroviral therapy early, but the results are likely to be surprising.

Published
25 November 2014
From
The Body
Narrow Time Window Exists to Start HIV Therapy, Study Shows

HIV-1-infected U.S. military members and beneficiaries treated with antiretroviral therapy (ART) soon after infection were half as likely to develop AIDS and were more likely to reconstitute their immune-fighting CD4+ T-cells to normal levels, researchers reported Nov. 24 in JAMA Internal Medicine.

Published
25 November 2014
From
Infection Control Today
NNRTI + 3 NRTIs may be strong first regimen in UK/Ireland children

Children starting antiretroviral therapy (ART) with a nonnucleoside (NNRTI) plus 3 nucleosides (NRTIs) had the lowest 2-year virologic failure rate in a study of 997 children in the United Kingdom and Ireland. Five-year toxicity rates were similar with the NNRTI and protease inhibitor (PI) regimens studied.

Published
24 November 2014
From
International AIDS Society
Positive response to 'gift tokens for undetectable viral load' trial

A US study presented at last month’s HIV Research for Prevention conference found generally positive responses among people with HIV and clinic staff to a trial that

Published
24 November 2014
By
Gus Cairns
The Guy Who Delivers HIV Medicine On His Bicycle

Sizwe Nzima was a high school student in Cape Town, South Africa, when he would pick up the medicine for his HIV-positive grandparents, who had difficulty traveling to the clinic themselves. Because of the long lines, Nzima usually waited hours and often made multiple trips to the clinic before and after school. So there he was, sitting on a hard wooden bench at the clinic one day about four years ago, when he had an idea: Why not start an HIV medicine delivery service?

Published
18 November 2014
From
NPR (blog)
Interim Revision of Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

This interim revision of the Guidelines includes a revised section on Hepatitis C Virus (HCV)/HIV Coinfection, with emphasis on considerations for use of antiretroviral (ARV) drugs in patients who also receive treatment for HCV infection. A new table (Table 12) provides clinicians with guidance on the concomitant use of HCV drugs and ARV drugs, with a focus on potential pharmacokinetic drug interactions. The Panel refers clinicians to http://www.hcvguidelines.org for guidance on the diagnosis and treatment of HCV infections.

Published
17 November 2014
From
AidsInfo
HIV Drug Development Pipeline Update, Fall 2014 Edition

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. At IDWeek 2014 in Philadelphia, Paul Sax, M.D., made the case for this new generation of drugs, and provided an update on several of the most noteworthy candidates currently in development.

Published
17 November 2014
From
The Body Pro
← First12345...372Next →

Filter by country